Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies

Richard J. Epstein\textsuperscript{1,2} and Thomas W. Leung\textsuperscript{2}

Abstract

The liver is distinguished from other tissues by (a) its detoxifying function, (b) its resistance to apoptosis, and (c) its regenerative response to damage. Hepatocellular carcinoma arises when chronic insults, such as hepatitis or iron overload, constitutively activate this regenerative program. Here, we propose that the proliferative response of the liver to damage underlies the resistance of hepatocellular carcinoma to cytotoxic therapy, and that hepatocellular carcinoma growth should therefore be more readily controlled by using a networked combination of noncytotoxic interventions to interrupt the damage-inducible regenerative pathway. To this end, hepatocellular carcinoma boasts a wealth of potential drug targets, including viral replication, the antiapoptotic immunosuppressant α-fetoprotein, hepatic iron overload, inflammatory signaling, extracellular proteases, and growth factors. By blocking these positive feedback loops in parallel, and so returning the host environment to a more normal state, epigenetic repression of tumor-suppressor gene function may be reversed and tumor dormancy restored. Noncytotoxic maneuvers that short circuit damage resistance loops may thus represent an indirect form of gene therapy meriting incorporation into hepatocellular carcinoma clinical trials.

Therapeutic progress in established hepatocellular carcinoma has largely been restricted to locoregional interventions. In the usual context of unresectable disease, response rates for ablative therapies (transcatheter arterial chemoembolization, ethanol injection, and radiofrequency ablation) have been gratifying; however, randomized proof of survival benefit remains elusive. Major improvements in the natural history of advanced hepatocellular carcinoma thus seem dependent on a quantum leap in medical therapy.

Several obstacles block this goal. First, the drug resistance of hepatocellular carcinoma means that no standard therapy exists against which to compare innovative regimens. Second, coexisting liver dysfunction all too often mandates management of "two diseases," and reduces the number of patients eligible for trials (1). Third, the inability thus far to identify typical hepatocellular carcinoma signaling pathologies (e.g., akin to epidermal growth factor receptor mutations in non-smoking lung adenocarcinoma, or HER2 overexpression in breast cancer) challenges rational design of target-based drug trials.

The traditional “magic bullet” approach to hepatocellular carcinoma drug development is based on the assumption that cancers are irreversible states that no longer respond to discrete signaling changes. This hypothesis has recently been challenged by the discovery that inactivation of a single oncogene can cause hepatocellular carcinoma to regress to a dormant state (2). It may thus be timely to consider a less hard-wired “reverse biology” model of hepatocellular carcinoma control in which well-characterized tumorigenetic steps are targeted in a coordinated manner using a network-based approach.

Detoxifying without Dying

The liver is a defensive organ that responds to damage in a unique manner. Nonhepatic epithelial cells progress through the cell cycle (i.e., G\textsubscript{1}–S–G\textsubscript{2}–M) until damaged, when they either die or arrest/repair; in contrast, growth-arrested (i.e., G\textsubscript{0}) hepatocytes proliferate in response to damage (Fig. 1; ref. 3). This antiapoptotic phenotype, which has evolved to suit the native detoxifying capacity of the liver after up-regulation by damage, is mediated by the high DNA repair capacity of the liver after up-regulation by damage.

Sublethal hepatocyte damage induces pro-inflammatory cytokine release, whereas harsher insults cause cell necrosis detectable as rupture of transaminases into the bloodstream. In contrast to the tumoriglytic significance of apoptosis, necrosis drives hepatocellular carcinoma initiation and progression (4), consistent with the absence of survival benefits of local ablation. Hence, the native detoxifying capacity of the liver suggests that hepatocellular carcinoma may inactivate cytoxins with unusual efficiency, whereas the high apoptotic threshold of the hepatocyte predicts that hepatocellular carcinoma damage will tend to cause necrogenic progression rather than remission.

Damage-Inducible Growth

The regenerative hepatic phenotype induced by wounding, resection, infection, or cytotoxic damage is central to the
hepatocellular carcinoma treatment dilemma. Cirrhosis impairs hepatic regenerativity, whereas necrotic release of hepatic survival factors drives regeneration of cirrhotic nodules (5). Treatment of hepatocellular carcinoma patients with chemotherapy may thus risk both acute hepatocellular decompensation and tumor progression. One approach to this problem involves using noncytotoxic therapies to block necrogenic pathways. This strategy is consistent with the reversible phenotype of many tumors (e.g., regression of gastric mucosal-associated lymphoid tissue lymphoma following *Helicobacter pylori* eradication, remission of EBV-associated lymphomas in response to antiviral therapy, or cytokine-driven involution of skin keratoacanthomas) and is supported by the status of hepatocellular carcinoma as the most frequent human cancer to undergo spontaneous regression (Fig. 2).

Progression of hepatocellular carcinoma involves selection for loss of proapoptotic tumor-suppressor gene function, as well as repression of DNA repair genes by mutation or promoter methylation. Because hepatitis activates the regenerative pathway, and because infection is a tumorigenic source of DNA damage, effective inhibition of viral inflammation could help to arrest hepatocellular carcinoma suppression (6) as one component of a more broad-based therapeutic strategy.

**Hit and Run, or Caught Red Handed?**

Chronic hepatitis virus infection affects over half a billion individuals [70% hepatitis B virus (HBV) and 30% HCV] worldwide and accounts for over 80% of the global incidence of hepatocellular carcinoma. Vertical transmission of HBV from mother to newborn is the highest-risk mode of viral carcinogenesis, predisposing to hepatocellular carcinoma even in noncirrhotic livers of infected offspring (7). Steroid treatment increases mortality of patients with chronic HBV, yet co-infection with HIV does not increase HBV-associated hepatocellular carcinoma (8), implying that it is the immune response to chronic infection that promotes hepatocellular carcinoma progression.

If hepatocellular carcinoma progression is not in fact driven by viral infection, the tumor may be better regarded as a "hit-and-run" complication of an earlier phase of infection, reducing prospects for intervention. Against the hit-and-run model is the fact that virally induced hepatocellular carcinoma exhibits few specific molecular stigmata of an earlier pathogenic event, unlike, say, aflatoxin-induced hepatocellular carcinoma (characterized by the TP53 codon 249 G→T transversion). If virus activity does drive tumor progression, on the other hand (i.e., the "caught-red-handed" model of viral hepatocarcinogenesis), then inhibition of HBV/HCV–dependent signaling or inflammation should slow tumor recurrence. This possibility is supported by a lower hepatocellular carcinoma frequency in HCV carriers in whom transaminitis is reduced with the use of the anticholestatic agent ursodiol (9).

**Gene Methylation: The Defense of DNA**

Despite many reports of HBV insertional mutagenesis in host genomes, evidence for a necessary role of HBV integration in hepatocyte transformation remains weak. A more general mode of viral carcinogenesis involves the defensive response of host cell genomes to intracellular viral DNA (10)—a response involving regional chromatin modification by cytosine methyltransferases and histone deacetylases, leading to transcriptional silencing.
Both HBV- and HCV-associated hepatocellular carcinomas are more frequently associated with epigenetic gene silencing than is nonviral hepatocellular carcinoma; however, there is little difference in the patterns of gene inactivation induced by the DNA virus HBV and the nonintegrating RNA virus HCV (11), indicating that integration is not necessary to induce DNA methylation. Viral load correlates with methylation of tumor-suppressor genes such as INK4A (12), suggesting that effective antiviral therapies could help to restore apoptotic susceptibility (Fig. 3).

**X Marks the Spot**

The apoptosis-regulatory TP53 gene lacks a promoter CpG island, making it resistant to methylation-dependent transcriptional repression. However, viruses have evolved other strategies to block the death of infected cells and thus potentiate viral chronicity. One example is the X protein of HBV (HBx), which directly inhibits p53, blocking transactivation of proapoptotic substrates (13). Conversely, HBV-inhibitory drugs, such as oltipraz, enhance death of infected cells by inducing TP53, implying that HBV antivirals can improve hepatocellular carcinoma chemosensitivity by acting as an indirect form of gene therapy (14).

HBx transactivates the hepatocyte x-fetoprotein (AFP) gene via the same CAAT/enhancer binding protein α site that normally opposes growth by restricting developmental expression of AFP; CAAT/enhancer binding protein α growth control may also be subverted by phosphatidylinositol 3-kinase/Akt signaling such as is involved in liver regeneration (15). Because the CAAT/enhancer binding protein α–blocking action of HBx evolved via selection for HBV-infected hepatocyte survival, a tumor-promoting function for AFP is implied.

**From Tumor Marker to Antitumor Target**

AFP, a glycoprotein structurally related to albumin but reciprocally regulated, is expressed in pregnancy by yolk sac and fetal liver from 6 weeks of gestation; in this context, AFP has been linked to “fetal graft” tolerance (16). Consistent with this immunomodulatory hypothesis, transplacental passage of fetal AFP is associated with clinical remission of rheumatoid arthritis.
and multiple sclerosis; conversely, a hazard of AFP functional blockade in viral liver disease is that of immune reconstitution hepatitis (17). The AFP gene is reactivated in adult liver following wounding, peaking 1 to 4 days after transaminase elevation. This time course parallels hepatic regeneration, as illustrated by correlation of high AFP levels with recovery from acetaminophen-induced hepatotoxicity (18).

Although AFP has long been used by oncologists as a marker for hepatocellular carcinoma or yolk sac tumors, this so-called oncofetal antigen remains a neglected drug target despite many observations implicating it as a mediator of hepatocellular carcinoma progression: (a) AFP-dependent immunosuppression is associated with hepatocellular carcinoma recurrence (19); (b) hepatocellular carcinoma cell growth is stimulated by purified AFP (20); (c) hepatocellular carcinoma cell growth is reversed by albumin overexpression (21), suggesting that hepatocellular carcinoma progression may be slowed by reversing hypoalbuminemia; (d) AFP antibodies block onco-gene expression in vitro and reverse hepatocellular carcinoma drug resistance in vivo (22); and (e) vaccination with AFP-encoding DNA inhibits xenograft growth (23). Hepatic AFP expression can be blocked by repressing HBx-dependent AFP transactivation using anti-HBV drugs (24), supporting the feasibility of this treatment in hepatocellular carcinoma; in estrogen-dependent breast cancer, however, hepatocellular carcinoma–derived AFP induces tumor regression (25). This raises questions about the role of sex hormones in hepatocellular carcinoma, which is 2- to 4-fold more common in males.

**The Sex Connection**

Hepatocellular carcinoma risk among HBV-infected males correlates with serum testosterone levels (26). Moreover, HBV surface antigen expression is up-regulated by androgens, supporting the hypothesis that hepatocarcinogenesis may be androgen dependent. Despite positive early trials of antiandrogen therapy, however, recent studies have failed to confirm survival prolongation (27). Treating estrogen receptor–positive hepatocellular carcinoma with tamoxifen has also yielded negative results at all dosage levels (28), whereas mixed outcomes have been reported with progestins. A potential therapeutic role for estrogens in hepatocellular carcinoma has been suggested by (a) the hepatoprotective effects of estrogens (29); (b) the good prognostic hepatocellular carcinoma implications of wild-type estrogen receptor expression, female gender, and oral contraceptive use (30); (c) estrogen-inducible inhibition of HBV DNA transcription and HBV E-antigen levels (31); and (d) estrogen-dependent induction of hepatic tumor-suppressor genes, and involution of premalignant masses (32). The hypothesis that estrogens could reduce hepatocellular carcinoma risk has never been popular, however, reflecting widespread concerns over thrombogenicity, carcinogenicity, and the premorbid association with cirrhosis-associated hyper-estrogenemia.

**Re-regulating Receptors**

Hormones are long-distance regulators of local growth factor synthesis and release. One important liver-related growth factor signaling pathway is that initiated by hepatocyte growth factor (“scatter factor”) and its receptor c-Met, which is essential for hepatic regeneration (33). A comitogenic role with hepatocyte growth factor is exerted in hepatocellular carcinoma by insulin-like growth factor-I (IGF-I; ref. 34), the receptor for which is up-regulated by chronic viral hepatitis (35). IGF-I receptor signaling in hepatocellular carcinoma directly contributes to apoptotic resistance (36), which is readily reversed in vitro by small-molecule IGF-I receptor signaling inhibitors (37). Upstream regulation of IGF-I synthesis and secretion occurs via the growth hormone pathway; consistent with this, blockade of this pathway by the somatostatin receptor antagonist octreotide inhibits liver regeneration in animal models (38). Few clinical hepatocellular carcinoma responses to single-agent octreotide have been reported, however, suggesting the need for a more multitargeted therapeutic approach.

The teratogenic antiemetic/leprosy drug thalidomide inhibits vascular endothelial growth factor–dependent hepatocellular carcinoma progression, and also blocks signaling via the proinflammatory cytokines tumor necrosis factor-α (39). Fas activation induces release of transforming growth factor-α and thus promotes epidermal growth factor receptor–dependent hepatocyte growth, possibly accounting for the reported in vitro and in vivo efficacy of small-molecule inhibition of epidermal growth factor receptor in hepatocellular carcinoma (40). Similarly, the epithelial apoptogen and AFP repressor transforming growth factor-β1 is stromally up-regulated in hepatitis, contributing to hepatic fibrosis (41). As fibrotic liver damage is mediated by free radicals, transforming growth factor β–induced injury is worsened by intracellular colocalization of the oxidative electron scavenger, iron.

**Iron, The Forgotten Growth Factor**

Although seldom noted, the gender imbalance of hepatocellular carcinoma parallels the higher lifetime iron levels of adult males relative to (menstruating) females. Iron excess is now firmly implicated in susceptibility to cancers, including hepatocellular carcinoma, even in women; the iron-transport protein transferrin likewise promotes tumor (including hepatocellular carcinoma) metastasis (42). That iron is a direct carcinogen is indicated by the elevated incidence of hepatocellular carcinoma in noncirrhotic iron-overloaded patients with idiopathic hemochromatosis (43). Moreover, although only 0.5% of Caucasians are heterozygous for the causal C282Y HFE gene mutation; a 25-fold higher frequency of this mutation occurs in hepatocellular carcinoma patients (44). Juvenile hemochromatosis can occur because of loss-of-function mutations affecting the HFE gene specifying the iron-regulatory peptide hepcidin. Activation of this gene by CAAT/enhancer binding protein α is blocked by HBx, leading to HBV chronicity and iron overload (45). Consistent with the antimicrobial properties of hepcidin, iron depletion protects against inflammatory damage (46), perhaps accounting for the ancient popularity of blood letting (phlebotomy, venesection). Tumors may likewise shrink after induction of iron-deficiency anemia by bleeding, whereas progression may be triggered by blood transfusions (47).

**Erythropoietin: Friend or Foe?**

Regenerating liver expresses the hypoxia-driven transactivator hypoxia inducible factor-1α, a key inducer of erythropoietin.
Clonal selection for polycythemia owing to erythropoietin overproduction by hepatocellular carcinoma could thus signify acquisition of a growth advantage via activation of the regenerative pathway. Like hypoxic stress, cytotoxic stress elevates erythropoietin levels, suggesting a further mechanism of drug resistance (48). Given the impaired survival reported in randomized studies of cancer patients (49), use of erythropoietin monotherapy in hepatocellular carcinoma seems inadvisable.

On the other hand, concurrent erythropoietin and phlebotomy/chelation efficiently redistributes iron stores and depletes free iron in both malignant and nonmalignant conditions (50). Combined iron depletion (e.g., chelation) and redistribution (erythropoietin) in hepatocellular carcinoma patients thus remains a promising antitumor manipulation. A further rationale for reversal of iron overload relates to the role of this element in metalloprotease activation.

The Promise of Proteases

Extracellular proteases cleave growth factor precursors or their binding proteins—stimulating growth factor-dependent cell motility and thus raising the therapeutic prospect of using protease inhibitors to block both preneoplastic hepatic fibrosis and hepatocellular carcinoma metastasis (51). Consistent with this possibility, the endogenous acute-phase reactant and serine protease inhibitor (serpin), α-1-antitrypsin—the genetic deficiency of which predisposes to hepatocellular carcinoma—hinders growth of HBV-infected liver cells (52).

A complicating factor lies in the recent insight that certain proteases may be tumor suppressive (53). For example, cisplatin suppresses cell surface proteases in tumor cells (54), but it is not known whether such protease suppression helps or hinders antitumor efficacy. Cisplatin also displaces iron from transferrin, increasing iron concentrations in chemotherapy-damaged tissues while potentially activating mitogenic metalloproteases and exacerbating metallothionein-mediated drug resistance (55). Effective anticancer exploitation of protease inhibitors may thus await greater knowledge.

Networking for Success

The advantages of pursuing a network approach to cancer therapeutics—as opposed to the one-off, target-based strategy that has dominated clinical trials to date—have become apparent with the growth of the systems biology field (56, 57). Networked therapeutic strategies focus not only on identifying discrete loci of fragility within tumor signaling pathways (58), the often-mutated \( \text{PIK3CA} \) gene in hepatocellular carcinoma being a relevant example (59), but also on synergistically inactivating polyvalent signaling crosstalk (60) that may otherwise create robustness (61) and drug resistance (62) within the meshwork of tissue-tumor interactions. Although immediate blockade of multiple interlocking pathways

<table>
<thead>
<tr>
<th>Target Pathways</th>
<th>Intervention</th>
<th>Antagonism</th>
<th>Hazards</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic HBV</td>
<td>HBV replication</td>
<td>Entecavir, HBIG</td>
<td>Steroids, Delta agent</td>
</tr>
<tr>
<td>Chronic HCV</td>
<td>HCV replication</td>
<td>IFN/ribavirin, ursodiol</td>
<td>Alcohol, HIV co-infection</td>
</tr>
<tr>
<td>Chronic inflammation/ Fibrosis</td>
<td>Integron TGF-β</td>
<td>Thalidomide, etanercept</td>
<td>Alcohol, iron overload</td>
</tr>
<tr>
<td>Regenerative signaling</td>
<td>TNFα/IFN-γ</td>
<td>Cytotoxic chemotherapy</td>
<td>Hepatotoxicity</td>
</tr>
<tr>
<td>HBx protein</td>
<td>IGF-IR/P13K signaling p53 inhibition, Akt/mTOR signaling</td>
<td>Oltipraz, temsirolimus</td>
<td>Delta agent</td>
</tr>
<tr>
<td>DNA methylation</td>
<td>Tumor-suppressor gene inactivation</td>
<td>Decitabine, valproate</td>
<td>Uncontrolled viral hepatitis</td>
</tr>
<tr>
<td>Growth factor signaling</td>
<td>Immunosuppression, apoptosis inhibition</td>
<td>AFP antibodies, albumin</td>
<td>Benzodiazepines</td>
</tr>
<tr>
<td>Iron overload</td>
<td>Ras-Raf-ERK, VEGF signaling</td>
<td>Sorafenib, sunitinib, bevacizumab, statins</td>
<td>Obesity, hypercholesterolemia</td>
</tr>
<tr>
<td>Proteases</td>
<td>Extracellular proteases, trypsin</td>
<td>Protease inhibitors, heparanase inhibitors</td>
<td>Cisplatin, alcohol</td>
</tr>
</tbody>
</table>

Abbreviations: TNF-α, tumor necrosis factor-α; NF-κB, nuclear factor-κB; ERK, extracellular-regulated kinase; mTOR, mammalian target of rapamycin (pathway); HBIG, hepatitis B immunoglobulin; PI3K, phosphatidylinositol 3-kinase; VEGF, vascular endothelial growth factor.

Fig. 4. Distinction between "response" (left) and "reversion" (right), modeling how cytotoxic therapies could cause both higher responses and faster progression, leading to inferior survivals, compared with revertant therapies. CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.
is an attractive clinical strategy that promises high response rates (63), accelerated induction of selection and resistance could limit survival improvements (64) and thus come to favor more nuanced interventions in both induction and maintenance (adjuvant) treatment phases (65).

Table 1 summarizes some of the biologically based interventions that could be used for hepatocellular carcinoma in appropriate combinations with (or without) cytotoxic therapy. Not all of these are yet practical; for example, small-molecule inhibitors of PI3KCA, Akt, Met, and IGF-1 receptor are not yet licensed, nor are protease inhibitors of established relevance to hepatocellular carcinoma biology, whereas AFP antibodies have not yet been humanized for clinical trial evaluation. Nonetheless, more aggressive control of viral replication and iron overload is immediately applicable, as is vascular endothelial growth factor antibody therapy, mammalian target of rapamycin–inhibitory therapies, and semitargeted kinase inhibition using drugs such as sorafenib and sunitinib. Provided that drug companies can be persuaded to cooperate by providing free drugs for use in combination, academic units can immediately embark on an informative range of network-based biopharmaceutical control strategies.

Conclusions

When used alone to treat hepatocellular carcinoma, conventional cytotoxic therapy causes unwanted effects, such as tissue necrosis, regenerative signaling, iron imbalance, and erythropoietin up-regulation. In contrast, certain noncytotoxic interventions are capable of blocking hepatocellular carcinoma growth, restoring tumor dormancy, and/or enhancing apoptotic sensitivity to cytotoxic drugs. From the viewpoint of clinical trial end points, it is crucial to note that reversibility in this context does not equate with response (Fig. 4). Investigator-initiated trials are now needed to test whether such networked biological strategies—whether used for induction, maintenance, chemosensitization, or chemotherapy sparing—are indeed capable of reversing hepatocellular carcinoma progression in different clinical scenarios and thus of improving patient outcomes.

Acknowledgments

We thank Professors C.L. Lai, C.M. Lo, and Raymond Liang for critical review of the manuscript.

References

5. Fausto N. Growth factors in liver development, re- 
7. Companies can be persuaded to cooperate by providing free drugs for use in combination, academic units can immediately embark on an informative range of network-based biopharma- 
8. ceutical control strategies.

Table 1 summarizes some of the biologically based inter- 
9. ventions that could be used for hepatocellular carcinoma in appropriate combinations with (or without) cytotoxic therapy. Not all of these are yet practical; for example, small-molecule inhibitors of PI3KCA, Akt, Met, and IGF-1 receptor are not yet licensed, nor are protease inhibitors of established relevance to hepatocellular carcinoma biology, whereas AFP antibodies have not yet been humanized for clinical trial evaluation. Nonetheless, more aggressive control of viral replication and iron overload is immediately applicable, as is vascular endothelial growth factor antibody therapy, mammalian target of rapamycin–inhibitory therapies, and semitargeted kinase inhibition using drugs such as sorafenib and sunitinib. Provided that drug companies can be persuaded to cooperate by providing free drugs for use in combination, academic units can immediately embark on an informative range of network-based biopharmaceutical control strategies.

Conclusions

When used alone to treat hepatocellular carcinoma, conventional cytotoxic therapy causes unwanted effects, such as tissue necrosis, regenerative signaling, iron imbalance, and erythropoietin up-regulation. In contrast, certain noncytotoxic interventions are capable of blocking hepatocellular carcinoma growth, restoring tumor dormancy, and/or enhancing apoptotic sensitivity to cytotoxic drugs. From the viewpoint of clinical trial end points, it is crucial to note that reversibility in this context does not equate with response (Fig. 4). Investigator-initiated trials are now needed to test whether such networked biological strategies—whether used for induction, maintenance, chemosensitization, or chemotherapy sparing—are indeed capable of reversing hepatocellular carcinoma progression in different clinical scenarios and thus of improving patient outcomes.

Acknowledgments

We thank Professors C.L. Lai, C.M. Lo, and Raymond Liang for critical review of the manuscript.

References

5. Fausto N. Growth factors in liver development, re- 
7. Companies can be persuaded to cooperate by providing free drugs for use in combination, academic units can immediately embark on an informative range of network-based biopharma- 
8. ceutical control strategies.

Table 1 summarizes some of the biologically based inter- 
9. ventions that could be used for hepatocellular carcinoma in appropriate combinations with (or without) cytotoxic therapy. Not all of these are yet practical; for example, small-molecule inhibitors of PI3KCA, Akt, Met, and IGF-1 receptor are not yet licensed, nor are protease inhibitors of established relevance to hepatocellular carcinoma biology, whereas AFP antibodies have not yet been humanized for clinical trial evaluation. Nonetheless, more aggressive control of viral replication and iron overload is immediately applicable, as is vascular endothelial growth factor antibody therapy, mammalian target of rapamycin–inhibitory therapies, and semitargeted kinase inhibition using drugs such as sorafenib and sunitinib. Provided that drug companies can be persuaded to cooperate by providing free drugs for use in combination, academic units can immediately embark on an informative range of network-based biopharmaceutical control strategies.

Conclusions

When used alone to treat hepatocellular carcinoma, conventional cytotoxic therapy causes unwanted effects, such as tissue necrosis, regenerative signaling, iron imbalance, and erythropoietin up-regulation. In contrast, certain noncytotoxic interventions are capable of blocking hepatocellular carcinoma growth, restoring tumor dormancy, and/or enhancing apoptotic sensitivity to cytotoxic drugs. From the viewpoint of clinical trial end points, it is crucial to note that reversibility in this context does not equate with response (Fig. 4). Investigator-initiated trials are now needed to test whether such networked biological strategies—whether used for induction, maintenance, chemosensitization, or chemotherapy sparing—are indeed capable of reversing hepatocellular carcinoma progression in different clinical scenarios and thus of improving patient outcomes.

Acknowledgments

We thank Professors C.L. Lai, C.M. Lo, and Raymond Liang for critical review of the manuscript.
Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies

Richard J. Epstein and Thomas W. Leung


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/13/1/11

Cited articles
This article cites 64 articles, 16 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/13/1/11.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/13/1/11.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.